Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.32 |
| ▸ | CCR5 | P51681 | 2/20 | 0.32 |
| ▸ | CCR8 | P51685 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16664441 | 0.89 | ALDH1A1 (0.35) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL16664453 | 0.80 | HRH4 (0.32) | — | |
| SCHEMBL21603163 | 0.75 | GRM5 (0.44) | OPRK1GRM5 | |
| SCHEMBL23416642 | 0.74 | GAA (0.35) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL14853093 | 0.74 | CYP2C19 (0.45) | — | |
| SCHEMBL23349377 | 0.74 | HTR2C (0.38) | — | |
| SCHEMBL7923008 | 0.73 | GRM5 (0.54) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL7601862 | 0.73 | CYP11B2 (0.38) | — | |
| SCHEMBL23416716 | 0.72 | — | — | |
| SCHEMBL256380 | 0.71 | CYP3A4 (0.31) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339177-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2022-05-24 | — | — | US | disclosed |
| EP-3642193-B1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS AND RELATED COMPOSITION | ZHANG XIAOHU (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-20210155635-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2021-05-27 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| WO-2010050445-A1 | BICYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | CCR1 1872/4885CCR5 1490/4885CCR8 3179/4885 |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | CCR1 2595/4885CCR5 2683/4885CCR8 3247/4885 |
| US-11339177-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same | BAX, LITAF, PNLIP | CCR1 3311/4885CCR5 2209/4885CCR8 3349/4885 |
| US-20210155635-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND METHOD USING THE SAME | BAX, LITAF, PNLIP | CCR1 3311/4885CCR5 2209/4885CCR8 3349/4885 |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | CCR1 1735/4885CCR5 1257/4885CCR8 2443/4885 |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | CCR1 1735/4885CCR5 1257/4885CCR8 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.